潛伏性結核病檢測市場：現況分析及未來預測（2024-2032）

預計預測期內（2024-2032 年），潛伏性結核病檢測市場將以 7.8% 的複合年增長率大幅成長。這主要是因為全球結核病發生率不斷上升，檢測潛伏性結核病以預防活動性結核病的需求日益增加。此外，IGRA等診斷工具的改進提高了其在高風險群體中的有效性和利用率。此外，政府發起的結核病控制運動和強制性篩檢也促進了市場的成長。

根據測試類型，市場分為結核菌素皮膚試驗 (TST) 和乾擾素-γ釋放試驗 (IGRA)。幹擾素-γ釋放試驗（IGRA）將在2023年佔據市場的大部分佔有率。幹擾素-γ釋放試驗（IGRA）幾乎只在高收入國家和需要保護的人口中進行。除此之外，各公司也使用 IGRA 提供新的、更精確的測試，例如 QuantiFERON-TB 和 T-SPOT.TB，並提高自動化診斷過程的效率。我們的目標是與醫療機構合作，將 IGRA 納入常規篩檢，並提高 PoA 中 IGRA 的可用性。人們對精確​​的診斷設備的需求很高，而且這項技術與當前和未來的醫療保健系統高度相關。

2024 年 3 月 18 日，QIAGEN (NYSE: QGEN; 法蘭克福證券交易所代碼：QIA) 宣佈與國際小組醫生協會 (IPPA) 建立合作夥伴關係，以支持和教育世界各地的小組醫生瞭解最新的結核病篩檢要求。特別是，我們將重點關注新的干擾素-γ釋放試驗（IGRA）的要求以及對患者和醫療保健提供者的相關益處。

根據應用，市場分為結核病患者家庭接觸者 (HHC)、愛滋病毒感染者 (PLHIV) 和其他。預測期內（2024-2032 年），愛滋病毒感染率預計將以顯著的複合年增長率成長。愛滋病毒感染者罹患活動性結核病的風險很高，因此需要定期進行準確的檢測，因而是潛伏性結核病檢測的最大消費者。近期，愛滋病護理計畫中結核病診斷的全球擴展增加了對諸如 IGRA 之類的性別特定且高度準確的測試的需求。公司正在與愛滋病診所和非政府組織建立合作夥伴關係，提供特定的檢測解決方案，並透過向這一高風險群體提供價格合理、方便可擴展的檢測解決方案來招募患者。

根據最終用戶，市場分為診斷實驗室、醫院/診所以及學術和研究機構。 2023 年，診斷實驗室將佔據市場的大部分佔有率。診斷實驗室是潛伏性結核病檢測中心的主要作用，尤其是在城市和半城市地區。擴大先進診斷設備的使用範圍並確保結果的準確性推動了成長。為了支援這一領域，公司提供和安裝 IGRA 自動化系統，實施高效實驗室營運解決方案，並提供將結果輕鬆整合到臨床環境中的技術。

為了更瞭解潛伏性結核病檢測的市場採用情況，根據北美（美國、加拿大和北美其他地區）、歐洲（德國、法國、英國、西班牙、義大利和歐洲其他地區）、亞太地區（中國、日本、印度和亞太地區其他地區）和世界其他地區的全球存在情況對市場進行了分析。預計預測期內（2024-2032 年）亞太地區將以顯著的複合年增長率成長。這是由於結核病發病率高、人們對結核病認識的提高以及全國為消滅結核病所做的努力。根據世界衛生組織 (WHO) 的數據，2022 年八個國家的結核病病例佔世界結核病病例的三分之二以上：印度（27%）、印尼（10%）、中國（7.1%）、菲律賓（7.0%）、巴基斯坦（5.7%）、奈及利亞（4.5%）、孟加拉（3.6%）和剛果民主共和國（3.0%）。此外，印度、中國等國家也在國際組織合作下進行大規模篩檢。例如，這可能包括提供低成本的診斷解決方案、與政府機構合作以及增加產品有限地區的市場覆蓋率。在城市地區，從傳統 TST 向先進的 IGRA 的轉變也支持了市場成長。

在市場上營運的主要公司包括 QIAGEN、Revvity、Abbott、BIOMERIEUX、Serum Institute of India Pvt.Ltd.、Lionex GmbH、SD Biosensor, INC.、Cepheid、Wantai BioPharm 和 AdvaCare Pharma。

目錄

第一章 市場概覽

• 市場定義
• 主要目的
• 利害關係人
• 限制

第 2 章 分析方法或假設

• 分析過程
• 分析法
• 受訪者資料

第 3 章執行摘要

• 產業摘要
• 各細分市場的展望
  • 市場成長強勁
• 區域展望

第 4 章 市場動態

• 驅動程式
• 機會
• 阻礙因素
• 趨勢
• PESTEL 分析
• 需求方分析
• 供給面分析
  • 併購 (M&A)
  • 投資場景
  • 產業洞察：領先的新創公司及其獨特策略

第 5 章 定價分析

• 價格分析：依地區
• 影響價格的因素

第六章 全球潛伏性結核病檢測市場收入（2022-2032）

第 7 章。

• 結核菌素皮膚試驗 (TST)
• 幹擾素-γ釋放試驗（IGRA）

第 8 章 依應用劃分的市場分析

• 結核病患者的家庭接觸者 (HHC)
• 愛滋病毒感染者 (PLHIV)
• 其他

第 9 章 最終使用者的市場分析

• 診斷實驗室
• 醫院/診所
• 學術和研究機構

第 10 章 各區域市場分析

• 北美洲
  • 美國
  • 加拿大
  • 其他北美地區
• 歐洲
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 義大利
  • 其他歐洲地區
  亞太地區
  • 中國
  • 日本
  • 印度
  • 其他亞太地區
• 世界其他地區

第 11 章 價值鏈分析

• 邊際分析
• 市場參與者名單

第 12 章 競爭格局

• 競爭資訊中心
• 公司市場定位分析
• 波特五力分析

第 13 章 公司簡介

凱傑公司
• 公司概況
• 主要財務指標
• SWOT 分析
• 產品組合
• 近期趨勢
• Revvity
• Abbott
• BIOMERIEUX
• Serum Institute of India Pvt. Ltd.
• Lionex GmbH
• SD Biosensor, INC.
• Cepheid
• Wantai BioPharm
• AdvaCare Pharma

第 14 章 縮寫與先決條件

第 15 章附錄

Latent TB Testing determines individuals with asymptomatic Mycobacterium tuberculosis infection who are likely to develop overt TB. Screening tests include the Tuberculin Skin Test (TST) and Interferon Gamma Release Assays (IGRAs), which identify a body's reaction to the bacteria. These tests are important in the prevention of TB epidemics among multiple risk groups such as the immunocompromised as well as the healthcare givers.

The Latent TB Testing Market is expected to grow with a significant CAGR of 7.8% during the forecast period (2024-2032). This is mainly due to the increasing rates of tuberculosis across the world increasing the need to detect latent TB to prevent active TB. Also, improvements in diagnostic tools like IGRAs increase the effectiveness and utilization in high-risk groups. In addition, TB control campaigns supported by the government and compulsory screening norms also contribute to the growth of the market.

Based on the test type, the market is segmented into Tuberculin Skin Test (TST), and Interferon Gamma Released Assay (IGRA). The Interferon Gamma Released Assay (IGRA) held a significant share of the market in 2023. The Interferon Gamma Released Assay (IGRA). It is implemented almost exclusively in high-income countries and among the populations in need of protection. Adding to this, IGRA is used by companies to provide new, more precise tests, such as QuantiFERON-TB and T-SPOT.TB, and to increase the efficiency of diagnostic process automation. They aim to cooperate with healthcare organizations to include IGRAs in regular check-ups and increase the availability of IGRAs via point of care. This technology has high relevance in the current and future healthcare systems since there is a great need for accurate diagnostic equipment.

On March 18, 2024, QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements. A special focus will be on the new Interferon Gamma Release Assay (IGRA) requirements and the associated benefits for patients and healthcare providers.

Based on application, the market is segmented into household contacts (HHC) of tuberculosis (TB) patients, people living with HIV (PLHIV), and others. People living with HIV are expected to grow with a significant CAGR during the forecast period (2024-2032). The PLHIV segment is one of the primary consumers in the latent TB testing market because such patients have a higher risk of developing active TB and, therefore, require regular and accurate tests. The recent expansion of tuberculosis diagnostics in HIV care programs worldwide has boosted the need for gender-precise and accurate tests such as IGRAs. Companies adopt by developing partnerships with HIV clinics and NGOs to deliver specific test solutions and by providing affordable easy-to-scale testing solutions to this risky group.

Based on the end user, the market is segmented into diagnostic laboratories, hospitals/clinics, and academic & research institutions. Diagnostic Laboratories held a significant share of the market in 2023. Diagnostic laboratories are major players as the testing centers for latent TB, especially in urban and semi-urban settings. They enhance growth by expanding access to high-level diagnostic equipment and guaranteeing the accuracy of results. To support this segment, companies supply and install IGRA automation systems, implement solutions for efficient lab operations, and provide technology for easy integration of the results into the clinical environment.

For a better understanding of the market adoption of Latent TB Testing, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, France, U.K., Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. Asia-Pacific is expected to grow with a significant CAGR during the forecast period (2024-2032). This is due to a high tuberculosis incidence rate, improved understanding of the disease, and national efforts to eliminate the disease. As per the World Health Organization, In 2022, eight countries accounted for more than two-thirds of global TB cases: India (27%), Indonesia (10%), China (7.1%), the Philippines (7.0%), Pakistan (5.7%), Nigeria (4.5%), Bangladesh (3.6%) and the Democratic Republic of the Congo (3.0%). Adding to this, large-scale screening is being carried out in countries such as India and China with the help of international organizations. Examples include offering low-cost diagnostic solutions, forming alliances with government organizations, and increasing market coverage to areas that have limited access to the products. A shift from conventional TSTs to advanced IGRAs within the urban regions also supports the growth of the market.

Some of the major players operating in the market include QIAGEN, Revvity, Abbott, BIOMERIEUX, Serum Institute of India Pvt. Ltd., Lionex GmbH, SD Biosensor, INC., Cepheid, Wantai BioPharm, AdvaCare Pharma.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Latent TB Testing Market
• 2.2. Research Methodology of the Latent TB Testing Market
• 2.3. Respondent Profile

3.EXECUTIVE SUMMARY

• 3.1. Industry Synopsis
• 3.2. Segmental Outlook
  • 3.2.1. Market Growth Intensity
• 3.3. Regional Outlook

4.MARKET DYNAMICS

• 4.1. Drivers
• 4.2. Opportunity
• 4.3. Restraints
• 4.4. Trends
• 4.5. PESTEL Analysis
• 4.6. Demand Side Analysis
• 4.7. Supply Side Analysis
  • 4.7.1. Merger & Acquisition
  • 4.7.2. Investment Scenario
  • 4.7.3. Industry Insights: Leading Startups and Their Unique Strategies

5.PRICING ANALYSIS

• 5.1. Regional Pricing Analysis
• 5.2. Price Influencing Factors

6.GLOBAL LATENT TB TESTING MARKET REVENUE (USD BN), 2022-2032F

7.MARKET INSIGHTS BY TEST TYPE

• 7.1. Tuberculin Skin Test (TST)
• 7.2. Interferon Gamma Released Assay (IGRA)

8.MARKET INSIGHTS BY APPLICATION

• 8.1. Household Contacts (HHC) of Tuberculosis (TB) Patients
• 8.2. People Living with HIV (PLHIV)
• 8.3. Others

9.MARKET INSIGHTS BY END USER

• 9.1. Diagnostic Laboratories
• 9.2. Hospitals/clinics
• 9.3. Academic & Research Institutions

10.MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. France
  • 10.2.3. UK
  • 10.2.4. Spain
  • 10.2.5. Italy
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of APAC
• 10.4. Rest of the World

11.VALUE CHAIN ANALYSIS

• 11.1. Marginal Analysis
• 11.2. List of Market Participants

12.COMPETITIVE LANDSCAPE

• 12.1. Competition Dashboard
• 12.2. Competitor Market Positioning Analysis
• 12.3. Porter Five Forces Analysis

13.COMPANY PROFILES

• 13.1. QIAGEN
  • 13.1.1. Company Overview
  • 13.1.2. Key Financials
  • 13.1.3. SWOT Analysis
  • 13.1.4. Product Portfolio
  • 13.1.5. Recent Developments
• 13.2. Revvity
• 13.3. Abbott
• 13.4. BIOMERIEUX
• 13.5. Serum Institute of India Pvt. Ltd.
• 13.6. Lionex GmbH
• 13.7. SD Biosensor, INC.
• 13.8. Cepheid
• 13.9. Wantai BioPharm
• 13.10. AdvaCare Pharma

14.ACRONYMS & ASSUMPTION

15.ANNEXURE